CNS therapy is amongst the top 3 chronic therapeutic segments. It has been on the forefront of medical research due to its impact on DALY (Disability Adjusted Life Years) i.e. potential years lost due to disability.
The prevalence of CNS diseases is growing across the globe. Advancements in healthcare has improved life expectancy significantly, hence there is an increase in elderly population which has led to a rise in CNS related diseases that are linked to advancing age such as Alzheimer’s, Parkinson’s, Depression and Stroke.
In India, approximately 30 million people suffer from neurological disorders such as Epilepsy, Neuropathic pain, Depression, Alzheimer’s and Stroke.
Eris ventured in the CNS segment in 2017, with the objective of providing superior solutions for diseases like Epilepsy, Neuropathic Pain, Dementia, Depression and Stroke.